ArticleCancer cell international2016
MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene.
Article in Cancer cell international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- MiR-20a, a novel promising biomarker to predict prognosis in human cancer: a meta-analysis.BMC cancer · 2018Pooled it
- Exosomal miR-20a-5p derived from cisplatin-resistant osteosarcoma cells promotes chemoresistance via Inhibition of ferroptosis through targeting RUNX3.Scientific reports · 2025Article
- Emerging roles and therapeutic potential of non-coding RNA in osteosarcoma: a review.Medical oncology (Northwood, London, England) · 2025Review
- Metformin alleviates adriamycin resistance of osteosarcoma by declining YY1 to inhibit MDR1 transcriptional activity.BMC pharmacology & toxicology · 2023Article
- A validation study for the utility of serum microRNA as a diagnostic and prognostic marker in patients with osteosarcoma.Oncology letters · 2023Article
- Post-translational modifications of tubulin: their role in cancers and the regulation of signaling molecules.Cancer gene therapy · 2023Review
- miR-197-3p Promotes Osteosarcoma Stemness and Chemoresistance by Inhibiting SPOPL.Journal of clinical medicine · 2023Article
- Circular RNAs: pivotal role in the leukemogenesis and novel indicators for the diagnosis and prognosis of acute myeloid leukemia.Frontiers in oncology · 2023Review
- Regulatory mechanism of miR-20a-5p expression in Cancer.Cell death discovery · 2022Review
- Targeting non-coding RNAs to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2022Review
- KIF26B in the Prognosis and Immune Biomarking of Various Cancers: A Pan-Cancer Study.Journal of oncology · 2022Article
- Role of MicroRNAs in Human Osteosarcoma: Future Perspectives.Biomedicines · 2021Review
- MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia.PloS one · 2021Article
- Long Noncoding RNA DICER1-AS1 Functions in Methylation Regulation on the Multi-Drugresistance of Osteosarcoma CellsFrontiers in oncology · 2021Article
- Function and mechanisms of microRNA-20a in colorectal cancer.Experimental and therapeutic medicine · 2020Review
- lncRNA LSINCT5 Regulates miR-20a-5p/XIAP to Inhibit the Growth and Metastasis of Osteosarcoma Cells.OncoTargets and therapy · 2020Article
- Association of germline variation with the survival of women withNPJ breast cancer · 2020Article
- miRNA signatures in childhood sarcomas and their clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Review
- ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.International journal of molecular sciences · 2019Review
- miR-450b-5p loss mediated KIF26B activation promoted hepatocellular carcinoma progression by activating PI3K/AKT pathway.Cancer cell international · 2019Article
Corrections and comments
- Retracted
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemoresistance hinders curative cancer chemotherapy in osteosarcoma (OS), resulting in only an approximately 20 % survival rate in patients with metastatic disease at diagnosis. Identifying the mechanisms responsible for regulating chemotherapy resistance is crucial for improving OS treatment.
methodsThis study was performed in two human OS cell lines (the multi-chemosensitive OS cell line G-292 and the multi-chemoresistant OS cell line SJSA-1). The levels of miR-20a-5p and KIF26B mRNA expression were determined by quantitative real-time PCR. KIF26B protein levels were determined by western blot analysis. Cell viability was assessed by MTT assay. Apoptosis was evaluated by flow cytometry.
resultsWe found that miR-20a-5p was more highly expressed in G-292 cells than in SJSA-1 cells. Forced expression of miR-20a-5p counteracted OS cell chemoresistance in both cell culture and tumor xenografts in nude mice. One of miR-20a-5p's targets, kinesin family member 26B (KIF26B), was found to mediate the miR-20a-5p-induced reduction in OS chemoresistance by modulating the activities of the MAPK/ERK and cAMP/PKA signaling pathways.
conclusionsIn addition to providing mechanistic insights, our study revealed that miR-20a-5p and KIF26B contribute to OS chemoresistance and determined the roles of these genes in this process, which may be critical for characterizing drug responsiveness and overcoming chemoresistance in OS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.